Clinical trials: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Relapsing Multiple Sclerosis
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to…
- Trial name
- NCT07220252
- Testing
- Ublituximab, Fingolimod
- Where
- 6 sites in United States, Poland and 1 more
- Volunteers
- 240 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
- Trial name
- NCT06104683
- Testing
- Pirtobrutinib
- Where
- 4 sites in United States, Puerto Rico
- Sponsor
- Loxo Oncology, Inc.
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS).
- Trial name
- KATHAROS (NCT06444113)
- Testing
- Ofatunumab
- Where
- 15 sites in United States, Germany and 3 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20…
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06526000
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Novartis
Multiple Sclerosis
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex.
- Trial name
- SYNERGY (NCT01864148)
- Testing
- BIIB033, Avonex
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 419 people
- Sponsor
- Biogen
Multiple Sclerosis (MS)
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple…
- Trial name
- SUPPRESS (NCT03135249)
- Testing
- Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Relapsing Multiple Sclerosis
CDP323 Biomarker Study
Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.
- Trial name
- NCT00726648
- Testing
- CDP323
- Where
- 2 sites in United Kingdom
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Multiple Sclerosis, Healthy
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
This study aims to assess the effect of Gilenya on brain pathology and cognitive impairment over 6, 12, and 24 months in patients with relapsing MS using MRI, clinical data, and neurological assessments.
- Trial name
- GLT (NCT02021162)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Relapsing Multiple Sclerosis
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
We aim to assess the effect of Ofatumumab on microglial activation using [F-18]PBR06 PET in MS patients in relation to changes in serum markers, MRI abnormalities and clinical impairment longitudinally over 9 months.
- Trial name
- NCT04510220
- Testing
- Ofatumumab, [F-18]PBR06
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS).
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06395909
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Novartis
Relapsing Forms of Multiple Sclerosis
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal…
- Trial name
- RESPOND (NCT01903291)
- Testing
- dimethyl fumarate
- Where
- 62 sites in United States
- Volunteers
- 333 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Long-term Follow-up of Fingolimod Phase II Study Patients
This study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in FTY720D2201 (D2201). No study drug was given or required.
- Trial name
- ACROSS (NCT02307838)
- Testing
- Assessments arm
- Where
- 26 sites in Canada, Denmark and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT03737851
- Testing
- elezanumab
- Where
- 49 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- AbbVie
Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS.
- Trial name
- NCT05688436
- Testing
- Diroximel Fumarate, Alemtuzumab, Fingolimod
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen
Multiple Sclerosis
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT00484536
- Testing
- CDP323
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 232 people
- Sponsor
- UCB Pharma
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the…
- Trial name
- VASOSEP (NCT02580669)
- Testing
- Neuropsychological assessment, Neurologic consultation, MRIs (with vasoreactivity testing)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Relapsing Forms of Multiple Sclerosis
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).
- Trial name
- NCT04909502
- Testing
- EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD
- Where
- 4 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Emerald Health Pharmaceuticals
Multiple Sclerosis
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
- Trial name
- NCT02738775
- Testing
- Ublituximab
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS.
- Trial name
- PRO-MSACTIVE (NCT03589105)
- Testing
- Ocrelizumab 300 mg, Ocrelizumab 600 mg
- Where
- 46 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche